William Berry, MD
Hematology & Oncology · Raleigh, NCNPI 1043250590
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,065 of the $175,551 with a category attached, or 68.4%. Dendreon Pharmaceuticals LLC accounts for 72.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $62,946 and has fallen 87.9% since, to $7,603 in 2024. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $1227.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$127K
- Merck$34K
- Pfizer$6K
- Johnson & Johnson$5K
- AstraZeneca$2K
- Blue Earth Diagnostics$1K
- plus $719 from 5 others
Across 231 payments — averaging $7543.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Medivation LLC.$211K
- Pfizer$100K
- Janssen Research & Development, LLC$7K
What the payments were for
- Consulting fees$40,71023%
- Speaking & faculty fees$120,06568%
- Travel & lodging$12,5087%
- Food & beverage$2,1071%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 86 | $127,121 |
| Merck | 32 | $33,607 |
| Pfizer | 6 | $5,744 |
| Johnson & Johnson | 6 | $5,257 |
| AstraZeneca | 1 | $1,943 |
| Blue Earth Diagnostics | 2 | $1,160 |
| Sanofi | 5 | $434 |
| Sanofi-aventis U.S. LLC | 2 | $150 |
| Comsort, Inc | 1 | $100 |
| Novartis | 1 | $24 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$175,551 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 24 | $39,773 |
| Prednisone | 31 | $277 |
| Gabapentin | 15 | $189 |
| Dexamethasone | 11 | $182 |
| Potassium Chloride | 15 | $146 |
| Amiloride Hcl | 15 | $137 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Raleigh
- Robert ShepardRaleigh$107K
- Alan KritzRaleigh$58K
- Joel Rivera ConcepcionRaleigh$36K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.